NHS drug pricing: Dozens of MPs challenge Streeting’s new power

• Thirty-one MPs are challenging new powers given to Wes Streeting regarding NHS drug pricing.
• Critics argue these changes undermine the independence of Nice and benefit US pharmaceutical companies.
• The government claims the move increases patient access to innovative and life-changing medical treatments.

A group of 31 MPs from various parties have signed a motion opposing Wes Streeting. They disagree with the health secretary gaining the power to override Nice judgments on drug spending. This opposition includes members from the Labour, Green, Liberal Democrat, Independent, Scottish Nationalist, and Plaid Cymru parties.

The controversy stems from a statutory instrument linked to a drug-pricing agreement with the US administration. This regulation allows Streeting to direct cost-effectiveness thresholds for health technology. Critics, including John McDonnell, argue this removes the insulation that protected the NHS from pharmaceutical industry lobbying since 1999.

Legal and political concerns are growing regarding this shift. Former health secretary Andrew Lansley warned that these rules might conflict with the Health and Social Care Act 2012. He suggested the regulations could illegally influence the substance of recommendations normally made independently by Nice experts.

Health experts and economists warn of severe financial trade-offs. The Health Foundation and economist Eric Yang suggest higher drug costs will force difficult cuts to other services. They argue the NHS cannot afford a higher drugs bill given current demographic changes and funding pressures.

Strong criticism also came from the British Medical Journal and former Nice chief Samantha Roberts. They claim the deal sacrifices population health for corporate wealth. Roberts noted that spending more on medicines inevitably means fewer nurses or fewer hip replacements for patients.

The Department of Health and Social Care maintains that Nice independence remains fully protected. They argue the changes help secure innovative medicines, such as a new brain cancer drug for children. They insist guidance remains free from political interference to ensure taxpayer value.

The Association of the British Pharmaceutical Industry also supported the government. An ABPI spokesperson stated that ministers cannot dictate specific decisions. Instead, they believe the government is simply responsible for setting operational parameters while Nice retains its critical independence.